Lim TH, Lai TYY, Takahashi K, et al. - In the EVEREST II randomized clinical trial, researchers compared treatment outcomes of combination therapy with intravitreal ranibizumab and verteporfin photodynamic therapy vs ranibizumab monotherapy in polypoidal choroidal vasculopathy at month 24. They randomized 322 patients to receive ranibizumab, 0.5 mg, plus vPDT (combination therapy group; n = 168) or ranibizumab, 0.5 mg, plus sham PDT (monotherapy group; n = 154). Three consecutive monthly ranibizumab injections, followed by a pro re nata regimen, were administered to all participants. In addition, the participants were administered vPDT (combination group) or sham PDT (monotherapy group) on day 1, followed by a pro re nata regimen based on the presence of active polypoidal lesions. Outcomes suggest superiority of combination therapy to monotherapy in terms of adjusted mean best-corrected visual acuity gain and in terms of achieving complete absence of indocyanine green hyperfluorescence of polypoidal lesions with fewer ranibizumab injections. Data thereby suggest ranibizumab plus prompt verteporfin photodynamic therapy as more effective compared with ranibizumab monotherapy for polypoidal choroidal vasculopathy with reduced treatment burden.